FDA outlined concerns with Elevidys’ manufacturing at Catalent site, Form 483 shows
The Elevidys-related manufacturing shortfalls were described in one of two Form 483s tied to FDA inspections that came before Catalent’s layoff spree at its Maryland gene therapy manufacturing business.